Literature DB >> 12379631

Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis.

J Lam1, Y Abu-Amer, C A Nelson, D H Fremont, F P Ross, S L Teitelbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379631      PMCID： PMC1766716          DOI： 10.1136/ard.61.suppl_2.ii82

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  12 in total

1.  Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification.

Authors:  Y P Li; W Chen; Y Liang; E Li; P Stashenko
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

2.  Expression and regulation of RAB3 proteins in osteoclasts and their precursors.

Authors:  Y Abu-Amer; S L Teitelbaum; J C Chappel; P Schlesinger; F P Ross
Journal:  J Bone Miner Res       Date:  1999-11       Impact factor: 6.741

3.  Osteoclastic bone resorption by a polarized vacuolar proton pump.

Authors:  H C Blair; S L Teitelbaum; R Ghiselli; S Gluck
Journal:  Science       Date:  1989-08-25       Impact factor: 47.728

4.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

5.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.

Authors:  K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis.

Authors:  Y Abu-Amer; J Erdmann; L Alexopoulou; G Kollias; F P Ross; S L Teitelbaum
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

Review 7.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

8.  Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.

Authors:  J Lam; C A Nelson; F P Ross; S L Teitelbaum; D H Fremont
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

9.  Substrate recognition by osteoclast precursors induces C-src/microtubule association.

Authors:  Y Abu-Amer; F P Ross; P Schlesinger; M M Tondravi; S L Teitelbaum
Journal:  J Cell Biol       Date:  1997-04-07       Impact factor: 10.539

10.  Isolated osteoclasts resorb the organic and inorganic components of bone.

Authors:  H C Blair; A J Kahn; E C Crouch; J J Jeffrey; S L Teitelbaum
Journal:  J Cell Biol       Date:  1986-04       Impact factor: 10.539
View more
  18 in total

1.  Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts.

Authors:  Tao Ma; Kavitha Sadashivaiah; Nandakumar Madayiputhiya; Meenakshi A Chellaiah
Journal:  J Biol Chem       Date:  2010-07-22       Impact factor: 5.157

Review 2.  Theories concerning the pathogenesis of the acute charcot foot suggest future therapy.

Authors:  William J Jeffcoate
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

3.  The relationship between idiopathic bone cavity and orthodontic tooth movement: analysis of 44 cases.

Authors:  I Velez; M A Siegel; S M Mintz; R Rolle
Journal:  Dentomaxillofac Radiol       Date:  2010-03       Impact factor: 2.419

4.  Fucoidan Prevents RANKL-Stimulated Osteoclastogenesis and LPS-Induced Inflammatory Bone Loss via Regulation of Akt/GSK3β/PTEN/NFATc1 Signaling Pathway and Calcineurin Activity.

Authors:  Sheng-Hua Lu; Yi-Jan Hsia; Kuang-Chung Shih; Tz-Chong Chou
Journal:  Mar Drugs       Date:  2019-06-10       Impact factor: 5.118

5.  Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-κB activation.

Authors:  Karl Wu; Tzu-Hung Lin; Houng-Chi Liou; Dai-Hua Lu; Yi-Ru Chen; Wen-Mei Fu; Rong-Sen Yang
Journal:  Osteoporos Int       Date:  2013-02-12       Impact factor: 4.507

Review 6.  Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies.

Authors:  Yousef Abu-Amer; Isra Darwech; John C Clohisy
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

7.  Reduction of particle-induced osteolysis by interleukin-6 involves anti-inflammatory effect and inhibition of early osteoclast precursor differentiation.

Authors:  Michael Darowish; Ra'Kerry Rahman; Ping Li; Susan V Bukata; Jill Gelinas; Willis Huang; Lisa M Flick; Edward M Schwarz; Regis J O'Keefe
Journal:  Bone       Date:  2009-06-12       Impact factor: 4.398

Review 8.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

9.  The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy.

Authors:  Agbor Ndip; Alfred Williams; Edward B Jude; Ferdinand Serracino-Inglott; Steve Richardson; J V Smyth; Andrew J M Boulton; M Yvonne Alexander
Journal:  Diabetes       Date:  2011-06-09       Impact factor: 9.461

10.  Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot.

Authors:  Luigi Uccioli; Anna Sinistro; Cristiana Almerighi; Chiara Ciaprini; Antonella Cavazza; Laura Giurato; Valeria Ruotolo; Francesca Spasaro; Erika Vainieri; Giovanni Rocchi; Alberto Bergamini
Journal:  Diabetes Care       Date:  2009-10-30       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.